eBioscience,
an Affymetrix
(Nasdaq:AFFX) business, announces the availability of PrimeFlow™
RNA Assay, the first and only flow cytometry assay capable of
simultaneous detection of RNA and protein within millions of cells at
single-cell resolution. Current flow cytometry applications are limited
to antibody-based interrogation of cell surface and intracellular
proteins. With the novel PrimeFlow assay, researchers can now
incorporate the simultaneous analysis of RNA transcripts and proteins to
elevate their understanding of single-cell dynamics.
“Single-cell analysis is a rapidly growing field in biomedical research
that yields an unprecedented level of information,” said Filippos
Porichis, PhD, Director of the Ragon Institute of MGH, MIT and
Harvard’s International Programs and first author of a newly published
Nature Communications paper citing the use of RNA transcript with flow
cytometry. “PrimeFlow RNA Assay enables high throughput detection of RNA
and protein expression; therefore, it can be used to characterize,
mechanistically and phenotypically, co-expression of RNAs with the
functional proteins at the single-cell level. This assay, with a
user-friendly protocol that has many similarities with standard
antibody-staining procedures and data acquisition of flow cytometry, is
an invaluable tool for any immunology lab performing translational
research.”
“The major advantage of this technology is the ability to detect, with
high sensitivity, mRNAs for which flow cytometry antibodies against the
corresponding proteins perform poorly or are not available,” adds Dr.
Daniel Kaufmann, Research and Clinical Associate Professor, Dept. of
Medicine, University of Montreal. “Furthermore, the capability to
directly measure non-coding RNAs, whose critical functional roles are
increasingly recognized, in a heterogeneous cell population has vast
potential applications in cell biology.”
“Single-cell gene expression assays, such as PrimeFlow RNA Assay,
showcase one of the many exciting opportunities we have for integrating
cell analysis and genomics, which open up new avenues for innovation and
growth,” said Frank Witney, CEO and President of Affymetrix. “PrimeFlow
RNA Assay represents the capabilities and expertise of eBioscience and
Affymetrix brought together to enable the scientific community to
advance the understanding and application of biology for a better world.”
To further discuss potential applications of PrimeFlow RNA Assay, please
email us at MarketingDept@ebioscience.com.
PLEASE NOTE: eBioscience and PrimeFlow are trademarks of
eBioscience, Inc., and Affymetrix and the Affymetrix logo are trademarks
of Affymetrix, Inc. All other trademarks and product names are the
property of their respective owners.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous analysis of
biological systems at the cell, protein, and gene level, facilitating
the rapid translation of bench-top research into clinical and routine
use for human health and wellness. The Company provides leadership and
support, partnering with customers in pharmaceutical, diagnostic, and
biotechnology companies, as well as leading academic, government, and
non-profit research institutes in their quest to use biology for a
better world. More than 2,300 microarray systems have been shipped
around the world and more than 65,000 peer-reviewed papers have been
published citing Affymetrix technologies. Affymetrix is headquartered in
Santa Clara, California, and has manufacturing facilities in Cleveland,
Ohio, San Diego, Vienna, and Singapore. The Company has about 1,100
employees worldwide and maintains sales and distribution operations
across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix' "expectations," "beliefs," "hopes," "intentions,"
"strategies," or the like. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially for
Affymetrix from those projected. These and other risk factors are
discussed in Affymetrix' Form 10-K for the year ended December 31, 2013,
and other SEC reports for subsequent quarterly periods.
Copyright Business Wire 2014